These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29174199)

  • 21. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.
    Lee MH; Han W; Lee JE; Kim KS; Park H; Kim J; Bae SY; Shin HJ; Lee JW; Lee ES
    Cancer Res Treat; 2015 Apr; 47(2):208-14. PubMed ID: 25381828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
    Gradishar WJ; Hansen NM; Susnik B
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?
    Conlon N; Ross DS; Howard J; Catalano JP; Dickler MN; Tan LK
    Breast J; 2015; 21(5):514-9. PubMed ID: 26271749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
    Albanell J; Svedman C; Gligorov J; Holt SD; Bertelli G; Blohmer JU; Rouzier R; Lluch A; Eiermann W
    Eur J Cancer; 2016 Oct; 66():104-13. PubMed ID: 27544930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
    Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
    Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
    D'Alfonso TM; van Laar RK; Vahdat LT; Hussain W; Flinchum R; Brown N; John LS; Shin SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):705-15. PubMed ID: 23774991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
    Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
    Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling.
    Mamounas EP; Budd GT; Miller KD
    Clin Adv Hematol Oncol; 2008 Feb; 6(2 Suppl 3):1-8. PubMed ID: 18347556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test.
    Dvorak L; Dolan M; Fink J; Varghese L; Henriksen J; Gulbahce HE
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):196-9. PubMed ID: 22914611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.
    Kip M; Monteban H; Steuten L
    J Comp Eff Res; 2015 Sep; 4(5):433-45. PubMed ID: 25872415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Menopausal status does not predict Oncotype DX recurrence score.
    Carr DN; Vera N; Sun W; Lee MC; Hoover S; Fulp W; Acs G; Laronga C
    J Surg Res; 2015 Sep; 198(1):27-33. PubMed ID: 26095420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
    Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
    PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital.
    Bargallo JE; Lara F; Shaw-Dulin R; Perez-Sánchez V; Villarreal-Garza C; Maldonado-Martinez H; Mohar-Betancourt A; Yoshizawa C; Burke E; Decker T; Chao C
    J Surg Oncol; 2015 Feb; 111(2):203-7. PubMed ID: 25288020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
    Ademuyiwa FO; Miller A; O'Connor T; Edge SB; Thorat MA; Sledge GW; Levine E; Badve S
    Breast Cancer Res Treat; 2011 Apr; 126(3):797-802. PubMed ID: 21197567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
    Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.
    Sutton EJ; Oh JH; Dashevsky BZ; Veeraraghavan H; Apte AP; Thakur SB; Deasy JO; Morris EA
    J Magn Reson Imaging; 2015 Nov; 42(5):1398-406. PubMed ID: 25850931
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.